Biological Products, (No Diagnostic Substances) · DE · CIK 1739174
Developing phage-based therapies to target and kill specific harmful bacteria associated with chronic diseases
Comparable business profile · signals at a glance
In the 90 days to Mar 17, 2026: 1 sold $8.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 | Yeganeh ReuvenDirector,TenPercentOwner | Sell | 530,000 | $5.00 | $2.6M |
| Mar 16, 2026 | Yeganeh ReuvenDirector,TenPercentOwner | Sell | 450,000 | $5.00 | $2.3M |
| Mar 13, 2026 | Yeganeh ReuvenDirector,TenPercentOwner | Sell | 370,000 | $5.00 | $1.9M |
| Mar 12, 2026 | Yeganeh ReuvenDirector,TenPercentOwner | Sell | 300,000 | $5.00 | $1.5M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.